News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
224,699 Results
Type
Article (5026)
Company Profile (17)
Press Release (219656)
Section
Business (82196)
Career Advice (461)
Deals (15041)
Drug Delivery (8)
Drug Development (19064)
Employer Resources (30)
FDA (3674)
Job Trends (3900)
News (120097)
Policy (7499)
Tag
2024 BioCapital Digital (2)
2024 Biotech Beach Standard (1)
2024 Pharm Country Digital (1)
2025 Lone Star Bio Digital (1)
Academia (292)
Adcomms (3)
Allergies (9)
Alliances (14759)
ALS (19)
Alzheimer's disease (243)
Antibody-drug conjugate (ADC) (11)
Approvals (3689)
Artificial intelligence (39)
Autoimmune disease (2)
Automation (2)
Bankruptcy (97)
Best Places to Work (2862)
Biosimilars (11)
Biotechnology (21)
Bladder cancer (9)
Brain cancer (7)
Breast cancer (46)
Cancer (424)
Cardiovascular disease (21)
Career advice (391)
Career pathing (2)
CAR-T (29)
Cell therapy (100)
Cervical cancer (2)
Clinical research (15997)
Collaboration (161)
Compensation (148)
Complete response letters (2)
COVID-19 (301)
CRISPR (7)
C-suite (91)
Cystic fibrosis (16)
Data (486)
Depression (5)
Diabetes (38)
Diagnostics (2036)
Digital health (3)
Diversity, equity & inclusion (12)
Drug discovery (15)
Drug pricing (6)
Drug shortages (1)
Duchenne muscular dystrophy (11)
Earnings (40719)
Editorial (1)
Employer branding (6)
Employer resources (31)
Events (37640)
Executive appointments (281)
FDA (3905)
Featured Employer (6)
Fibrodysplasia Ossificans Progressiva (1)
Frontotemporal dementia (2)
Funding (174)
Gene editing (15)
Generative AI (2)
Gene therapy (45)
GLP-1 (105)
Government (407)
Guidances (16)
Healthcare (5035)
Huntington's disease (1)
IgA nephropathy (3)
Immunology and inflammation (13)
Indications (6)
Infectious disease (316)
Inflammatory bowel disease (24)
Inflation Reduction Act (2)
Influenza (3)
Intellectual property (15)
Interviews (53)
IPO (7814)
IRA (3)
Job creations (1120)
Job search strategy (360)
Kidney cancer (6)
Labor market (4)
Layoffs (100)
Leadership (4)
Legal (2330)
Liver cancer (17)
Lung cancer (50)
Lymphoma (27)
Management (10)
Manufacturing (45)
MASH (27)
Medical device (3855)
Medtech (3856)
Mergers & acquisitions (7416)
Metabolic disorders (113)
Multiple sclerosis (8)
NASH (6)
Neurodegenerative disease (9)
Neuropsychiatric disorders (1)
Neuroscience (331)
NextGen: Class of 2025 (1674)
Non-profit (727)
Northern California (869)
Now hiring (2)
Obesity (50)
Opinion (30)
Ovarian cancer (17)
Pain (12)
Pancreatic cancer (13)
Parkinson's disease (21)
Partnered (4)
Patents (21)
Patient recruitment (26)
Peanut (5)
People (24513)
Pharmaceutical (5)
Pharmacy benefit managers (1)
Phase I (4770)
Phase II (6946)
Phase III (5536)
Pipeline (518)
Policy (4)
Postmarket research (625)
Preclinical (1863)
Press Release (66)
Prostate cancer (26)
Psychedelics (3)
Radiopharmaceuticals (105)
Rare diseases (63)
Real estate (1872)
Recruiting (8)
Regulatory (5096)
Reports (14)
Research institute (300)
Resumes & cover letters (68)
Rett syndrome (2)
Schizophrenia (21)
Series A (25)
Series B (21)
Sickle cell disease (7)
Southern California (670)
Special edition (1)
Spinal muscular atrophy (28)
Sponsored (3)
Startups (1007)
Stomach cancer (1)
Supply chain (10)
United States (6660)
Vaccines (34)
Venture capitalists (2)
Webinars (4)
Weight loss (19)
Women's health (1)
Date
Today (78)
Last 7 days (262)
Last 30 days (924)
Last 365 days (10307)
2025 (2494)
2024 (11027)
2023 (13193)
2022 (18658)
2021 (19679)
2020 (18239)
2019 (13205)
2018 (10205)
2017 (10004)
2016 (9157)
2015 (12118)
2014 (9588)
2013 (7707)
2012 (8330)
2011 (8796)
2010 (8634)
Location
Africa (184)
Alabama (13)
Alaska (2)
Arizona (59)
Arkansas (1)
Asia (11430)
Australia (1600)
California (1821)
Canada (664)
China (67)
Colorado (77)
Connecticut (90)
Delaware (27)
Europe (24422)
Florida (254)
Georgia (32)
Idaho (23)
Illinois (109)
India (5)
Indiana (59)
Iowa (1)
Japan (64)
Kansas (24)
Kentucky (10)
Louisiana (5)
Maine (38)
Maryland (214)
Massachusetts (1465)
Michigan (84)
Minnesota (134)
Mississippi (1)
Missouri (21)
Montana (16)
Nebraska (12)
Nevada (22)
New Hampshire (15)
New Jersey (532)
New Mexico (5)
New York (452)
North Carolina (314)
North Dakota (2)
Northern California (869)
Ohio (54)
Oklahoma (5)
Oregon (3)
Pennsylvania (332)
Rhode Island (11)
South America (275)
South Carolina (4)
Southern California (670)
Tennessee (34)
Texas (215)
Utah (57)
Virginia (40)
Washington D.C. (8)
Washington State (160)
West Virginia (2)
Wisconsin (20)
224,699 Results for "cytrx corporation".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Biotech Beach
CytRx Corporation Relaunches as LadRx Corporation
CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, announces that it is relaunching as LadRx Corporation.
September 23, 2022
·
4 min read
Business
CytRx Welcomes Cary J. Claiborne to the CytRx Board of Directors
CytRx Corporation welcomes Mr. Cary J. Claiborne to the CytRx Board of Directors (the “Board”).
August 9, 2022
·
4 min read
Deals
CytRx Highlights Strategic Purchase of Arimoclomol by KemPharm, Inc.
CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, is pleased to highlight the strategic purchase of arimoclomol by KemPharm, Inc. (“KemPharm”).
May 17, 2022
·
4 min read
Policy
European Patent Office Awards CytRx Key Patent
CytRx Corporation, a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, announced it has been awarded a key patent by the European Patent Office, and that the period for parties to oppose the patent has lapsed without opposition.
September 7, 2022
·
3 min read
Biotech Beach
CytRx Announces Integration of Wholly Owned Subsidiary Centurion BioPharma and Corporate Governance Updates
CytRx Corporation, a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, announced that the Company is absorbing its wholly-owned subsidiary Centurion BioPharma Corporation.
March 9, 2022
·
4 min read
Press Releases
Corporate Update: Psyence Biomedical Ltd Redefines Psychedelic Medicine with a Multi-Asset Strategy, Advancing Clinical Trials and Scalable Manufacturing
Company executives will host a corporate webinar for investors and stakeholders on Thursday, April 10, 2025
March 31, 2025
·
12 min read
Biotech Beach
CytRx Partners with Oncology Development Expert to Advance LADR Platform
CytRx Corporation announced it has partnered with oncology development expert Gilad Gordon, MD to assist the Company in developing its next-generation LADR drugs toward first-in-human clinical trials.
April 20, 2022
·
4 min read
Business
CytRx Announces the Appointment of Dr. Stephen Snowdy as Chief Executive Officer
CytRx Corporation (OTCQB:CYTR) (“CytRx” or the “Company”), a specialized biopharmaceutical company focused on research and development in oncology and neurodegenerative diseases, today announced that it has appointed Dr. Stephen Snowdy to the role of Chief Executive Officer, effective January 10, 2022.
January 3, 2022
·
4 min read
Biotech Beach
CytRx Highlights Orphazyme’s Update on Planned NDA Resubmission for Arimoclomol in Niemann-Pick Disease Type C
CytRx Corporation today highlighted Orphazyme A/S for the treatment of Niemann-Pick disease type C (“NPC”). CytRx licensed arimoclomol to Orphazyme in exchange for milestone payments and royalties.
February 14, 2022
·
2 min read
Biotech Beach
CytRx to Participate in the H.C. Wainwright BioConnect Virtual Conference
CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today announced that John Caloz, the Company’s Chief Financial Officer, is scheduled to present at the H.C. Wainwright BioConnect Virtual Conference.
January 7, 2022
·
2 min read
1 of 22,470
Next